LPGAT1

Across TCGA pan-cancer cohorts, LPGAT1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of LPGAT1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where LPGAT1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types LPGAT1 is over-expressed in tumor.

CCRCC, PDAC, and COAD are the cancer types where LPGAT1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LPGAT1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	+0.886	<.001	11	view →
PDAC	Female	II,III,IV	+0.886	<.001	9	view →
COAD	Female	III,IV	+0.559	<.001	9	view →
LUAD	Female	II,III,IV	+0.426	<.001	9	view →
HNSC	All	All	+0.471	<.001	8	view →
LSCC	All	All	+0.144	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

LPGAT1–CCRCC

Open the CCRCC breakdown →